Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 23.75
-0.17 (-0.71%)
Oct 8, 2026, 3:04 PM CST
Hybio Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 20,977 | 15,810 | 11,385 | 11,994 | 15,527 | 11,138 | |
Market Cap Growth | 11.35% | 38.87% | -5.08% | -22.75% | 39.41% | 88.22% |
Enterprise Value | 22,758 | 17,616 | 13,122 | 13,710 | 17,024 | 12,784 |
Last Close Price | 23.75 | 17.90 | 12.89 | 13.58 | 17.58 | 12.61 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 166.88 | 432.32 | - | - | - | 361.52 |
Forward PE | - | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 |
PS Ratio | 18.98 | 16.36 | 19.29 | 27.80 | 22.05 | 15.13 |
PB Ratio | 24.25 | 25.10 | 19.07 | 15.31 | 11.97 | 6.76 |
P/TBV Ratio | 40.26 | 45.03 | 39.92 | 22.37 | 15.44 | 8.43 |
P/FCF Ratio | 957.19 | - | 232.96 | - | - | - |
P/OCF Ratio | 54.88 | 67.59 | 69.12 | - | 982.28 | 71.02 |
PEG Ratio | - | 0.73 | 0.73 | 0.73 | 0.73 | 0.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 20.59 | 18.23 | 22.23 | 31.78 | 24.17 | 17.37 |
EV/EBITDA Ratio | 68.25 | 58.98 | 114.07 | - | - | - |
EV/EBIT Ratio | 120.24 | 104.65 | - | - | - | - |
EV/FCF Ratio | 1038.47 | - | 268.51 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 2.22 | 3.03 | 3.01 | 2.59 | 1.39 | 1.09 |
Debt / EBITDA Ratio | 5.75 | 6.38 | 15.52 | - | - | - |
Debt / FCF Ratio | 87.48 | - | 36.79 | - | - | - |
Net Debt / Equity Ratio | 2.04 | 2.87 | 2.85 | 2.15 | 1.19 | 0.71 |
Net Debt / EBITDA Ratio | 5.31 | 6.05 | 14.80 | -7.57 | -29.27 | -8.09 |
Net Debt / FCF Ratio | 80.60 | -4020.51 | 34.83 | -19.76 | -8.85 | -27.80 |
Asset Turnover | 0.32 | 0.31 | 0.19 | 0.13 | 0.19 | 0.19 |
Inventory Turnover | 1.47 | 1.71 | 1.44 | 1.52 | 1.12 | 1.58 |
Quick Ratio | 0.20 | 0.14 | 0.14 | 0.36 | 0.52 | 1.28 |
Current Ratio | 0.46 | 0.29 | 0.33 | 0.48 | 0.71 | 1.55 |
Return on Equity (ROE) | 15.58% | 5.55% | -26.10% | -49.56% | -25.30% | 1.71% |
Return on Assets (ROA) | 3.42% | 3.42% | -0.64% | -6.74% | -3.03% | -4.26% |
Return on Invested Capital (ROIC) | 5.72% | 3.77% | -1.36% | -14.00% | -6.44% | -7.61% |
Return on Capital Employed (ROCE) | 9.70% | 12.30% | -2.00% | -20.00% | -7.40% | -8.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.61% | 0.23% | -1.52% | -4.28% | -2.39% | 0.28% |
FCF Yield | 0.10% | -0.00% | 0.43% | -0.71% | -1.12% | -0.38% |
Payout Ratio | 75.36% | 259.33% | - | - | - | 375.37% |
Buyback Yield / Dilution | -11.56% | -5.29% | 2.00% | -0.42% | 14.09% | -11.21% |
Total Shareholder Return | -11.56% | -5.29% | 2.00% | -0.42% | 14.09% | -11.21% |